Provectus Pharmaceuticals  Symbol: PVCT

Chosen AT $1.50 A Share

Officially Withdrawn At Peak Of Over $3.00 In September of 2007

Provectus Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops therapies designed to target and destroy breast cancer, liver cancer, and metastatic melanoma. The company is conducting clinical trials of their proprietary prescription drugs, Provecta (PV-10) as a therapy for melanoma and breast cancer, as well as Xantryl, a topical treatment for severe psoriasis and eczema.

In addition, it produces various over-the-counter skin care products, such as GloveAid, a hand cream with both antiperspirant and antibacterial properties, to enhance the comfort of users hands during and after the wearing of disposable gloves; and Pure-ific line of products that comprise two sprays, Pure-ific and Pure-ific Kids, which kill up germs on skin and prevent regrowth for six hours.

Further, Provectus Pharmaceuticals is developing various biotechnologies to augment vaccine production and detect viruses, including a virus hunter method, as well as licensing patented technologies for therapeutic and cosmetic medical devices.

The company was founded in 2002 is based in Knoxville, Tennessee.